Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+4.71%
$12.70
100% positive prob.
5-Day Prediction
+23.30%
$14.95
100% positive prob.
20-Day Prediction
+24.53%
$15.10
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +4.71% | +23.30% | +24.53% | 100.0% | Pending |
| Q2 2026 | SELL | -4.57% | -7.49% | -3.43% | 100.0% | +38.20% |
| Q1 2026 | SELL | -5.23% | -8.28% | -2.24% | 100.0% | -1.21% |
| Q4 2025 | BUY | +6.04% | +23.74% | +28.98% | 100.0% | +12.74% |
SEC 8-K filings with transcript text
Nov 12, 2026 · 100% conf.
1D
+4.71%
$12.70
Act: +1.15%
5D
+23.30%
$14.95
20D
+24.53%
$15.10
2 fdmt-ex99_1.htm
Exhibit 99.1
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights
and Expected Upcoming Milestones
• Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively
• Presented 2-year data from PRISM and SPECTRA clinical trials of 4D-150 in wet AMD and DME, highlighting durable clinical activity and favorable, predictable safety profile
• Initiated 4SIGHT Global Phase 3 clinical trial of 4D-150 in DME, advancing 4D-150 into second multi-billion-dollar retinal disease market with significant unmet need
• Strengthened regulatory affairs and quality teams through the hire of Eric Floyd, PhD, MBA, as Chief Regulatory & Quality Officer
• $375 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028
EMERYVILLE, Calif., November 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD,” said David Kirn, MD, Co-founder, President and Chief Executive Officer of 4DMT. “In addition, we initiated the global Phase 3 4SIGHT program in DME, expanding the opportunity for 4D-150 into a second multi-billion-dollar retinal disease market with significant unmet need. We also welcomed Dr. Eric Floyd to our executive team, providing experienced leadership for our regulatory team. We are well positioned heading into 2027, which we anticipate will be a transformative year for the Company following expected topline readouts from both 4FRONT Phase 3 trials in wet AMD.”
Recent Highlights and Expected Milestones
• Corporate Highlights:
o Strengthened leadership of Regulatory and Quality teams:
▪ Hired Dr. Eric Floyd as Chief Regulatory & Quality Officer. Dr. Floyd will oversee regulatory strategy, global engagements with regulatory authorities, quality assurance and quality control. Prior to joining 4DMT, Dr. Floyd served as Chief Regulatory Officer at Silence Therapeutics and Neurogene. He has held senior regulatory affairs and/or quality positions at large pharmaceutical companies including Merck, Sanofi and Novartis
o Company hosted an Investor Day in New York City on October 21, 2026:
▪ Provided insights into the current treatment landscape and unmet needs in wet age-related macular degeneration (wet AMD), the potential target product profile of 4D-150 and the commercial potential for 4D-150 to meaningfully improve patient outcomes
• 4D-150 for Wet Age-related Macular Degeneration (AMD):
o 4FRONT Global Phase 3 Program:
▪ 4FRONT-1, North American Clinical Trial:
• Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027
▪ 4FRONT-2, Global Clinical Trial:
• Enrollment completed in June 2026 and randomization completed (N=531) in August 2026; topline data expected in H2 2027
o PRISM Phase 1/2 Clinical Trial:
▪ Presented positive Phase 2b 2-year data in a broad patient population, including the recently diagnosed subgroup population most comparable to the 4FRONT Phase 3 population, at the American Society of Retina Specialists (ASRS) Annual Meeting on July 18, 2026, demonstrating durable maintenance of best corrected visual acuity (BCVA), control of central subfield thickness (CST) and clinically meaningful reduction in treatment burden, with a favorable and predictable safety profile
• 4D-150 for Diabetic Macular Edema (DME):
o 4SIGHT Global Phase 3 Clinical Trial:
▪ Initiated 4SIGHT, a global Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled trial of intravitreal 4D-150 in treatment-naïve patients with DME (N=514)
▪ All patients will receive five aflibercept loading doses. The primary endpoint is non-inferiority in the mean change from baseline in BCVA at Week 52. The key secondary endpoints are treatment burden reduction, comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm through Week 52, and the proportion of participants with a ≥2-step improvement from baseline in Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52
o SPECTRA Part 1 Clinical Trial:
▪ Updated 2-year data from SPECTRA Part 1 clinical trial in DME continue to d
Aug 13, 2026 · 100% conf.
1D
-4.57%
$11.12
Act: +4.64%
5D
-7.49%
$10.78
Act: +38.20%
20D
-3.43%
$11.25
2 fdmt-ex99_1.htm
Exhibit 99.1
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights
and Expected Upcoming Milestones
• Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027
• 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027
• Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS, highlighting long-term continuous treatment effect and ongoing favorable safety profile
• Plan to initiate a 4D-150 DME Phase 3 in Q3 2026
• Company to host an Investor Day on October 21, 2026, in New York City
• Entered into a strategic credit facility agreement with Hercules Capital, Inc. for up to $200 million, initial draw of $20 million
• $431 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028
EMERYVILLE, Calif., August 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
“The second quarter of 2026 reflected continued strong execution across 4DMT, including completion of enrollment for 4FRONT-2, presenting positive long-term PRISM data and strengthening our financial flexibility through securing a strategic credit facility with Hercules,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “With topline data from both 4FRONT-1 and 4FRONT-2 in wet AMD expected in 2027, our DME Phase 3 expected to initiate in the third quarter and our Investor Day planned in October, we are well positioned to advance 4D-150 as a potential paradigm-changing backbone therapy for patients with wet AMD and DME.”
Recent Highlights and Expected Milestones
• Corporate Highlights:
o Secured credit facility for up to $200 million from Hercules Capital to provide the Company with strategic and operational flexibility
▪ Under the terms of the agreement, the Company drew an initial $20 million at closing
o Company to host an Investor Day in New York City on October 21, 2026
▪ Investor Day will provide an overview of the commercial potential of 4D-150 and include participation from senior leadership and leading retinal disease key opinion leaders. Additional details will be provided in advance of the event
• 4D-150 for Wet Age-related Macular Degeneration (AMD):
o 4FRONT Global Phase 3 Program:
▪ 4FRONT-1, North American Clinical Trial:
• Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027
▪ 4FRONT-2, Global Clinical Trial:
• Enrollment completed in June 2026 with N>500 expected to be randomized; topline data expected in H2 2027
o PRISM Phase 1/2 Clinical Trial:
▪ Phase 2b 2-year data in a broad patient population, including the recently diagnosed subgroup population most comparable to the 4FRONT Phase 3 population, presented at American Society of Retina Specialists (ASRS) Annual Meeting on July 18, 2026:
• Consistent maintenance of best corrected visual acuity (BCVA)
• Consistent control of central subfield thickness (CST) as measured by optical coherence tomography
• Consistent, durable and clinically meaningful reduction in treatment burden:
o Overall cohort:
▪ 78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)
o Recently diagnosed subgroup:
▪ 87% overall treatment burden reduction (1.6 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)
• 4D-150 continues to be well tolerated with no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff and no 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date
• 4D-150 for Diabetic Macular Edema (DME):
o Global Phase 3 trial design and initiation expected in Q3 2026
o SPECTRA clinical trial 2-year data expected in Q4 2026
• 4D-175 for Geographic Atrophy:
o Company maintains an active IND and is evaluating opportunities to advance the program into the clinic
• 4D-710 for Cystic Fibrosis:
o AEROW Phase 1/2 clinical trial and program update expected in Q4 2026
Q2 2026 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, as compared to $514.0 million as of December 31, 2025. Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities, and expected payments under our collaboration agreement with Otsuka, will be sufficient to fund our operating expenses and ca
May 7, 2026 · 100% conf.
1D
-5.23%
$9.41
Act: +0.76%
5D
-8.28%
$9.11
Act: -1.21%
20D
-2.24%
$9.71
Act: -12.99%
2 fdmt-ex99_1.htm
Exhibit 99.1
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights
and Expected Upcoming Milestones
• 4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027
• 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027
• 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026
• $458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028
EMERYVILLE, Calif., May 7, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
“We started 2026 with strong execution, completing enrollment in 4FRONT-1 ahead of schedule reflecting strong investigator and patient enthusiasm for 4D-150,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “For the remainder of the year, we look forward to completing 4FRONT-2 enrollment, initiating our global Phase 3 clinical trial in DME, and sharing 2-year data from PRISM and SPECTRA.”
Recent Highlights and Expected Milestones
• 4D-150 for Wet Age-related Macular Degeneration:
o 4FRONT Global Phase 3 Program:
▪ 4FRONT-1, North American Clinical Trial:
• Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in H1 2027
▪ 4FRONT-2, Global Clinical Trial:
• Enrollment completion expected in H2 2026; topline data expected in H2 2027
o PRISM Phase 1/2 Clinical Trial:
▪ Phase 2b 2-year data in a broad patient population, including the recently diagnosed subgroup population most comparable to the 4FRONT Phase 3 population, expected to be presented at a scientific conference in Q3 2026
• 4D-150 for Diabetic Macular Edema:
o SPECTRA clinical trial 2-year data expected in H2 2026
o Global Phase 3 trial design expected in mid-2026 and initiation expected in Q3 2026
• 4D-175 for Geographic Atrophy:
o Company maintains an active IND and continues to evaluate strategic funding
alternatives to advance the program into the clinic
• 4D-710 for Cystic Fibrosis:
o AEROW Phase 1/2 clinical trial and program update expected in H2 2026
Q1 2026 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were $458 million as of March 31, 2026, as compared to $514 million as of December 31, 2025. Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities, and expected payments under our collaboration agreement with Otsuka, will be sufficient to fund our operating expenses and capital expenditure requirements at least into the second half of 2028.
Collaboration and License Revenue: Collaboration and license revenue was $3.0 million for the first quarter of 2026, as compared to an insignificant amount for the first quarter of 2025. The increase in revenue was primarily due to the clinical trial cost sharing and reimbursement amounts from Otsuka.
R&D Expenses: Research and development expenses were $65.0 million for the first quarter of 2026, as compared to $40.7 million for the first quarter of 2025. This increase was primarily driven by execution of 4D-150 Phase 3 clinical trials in wet AMD.
G&A Expenses: General and administrative expenses were $11.7 million for the first quarter of 2026, as compared to $12.9 million for the first quarter of 2025.
Net Loss: Net loss was $68.8 million for the first quarter of 2026, as compared to net loss of $48.0 million for the first quarter of 2025.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4D
This page provides 4D Molecular Therapeutics Inc. (FDMT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on FDMT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.